AGP Executive Report
Last update: 9 hours agoCBD in Autism Trial: SciSparc says NeuroThera’s SCI-210 study in Israel has hit 26 enrolled children (target 60), testing a CBD + CannAmide combo versus CBD alone for autism symptoms. Hemp Beverages Watch: Kick Fizz Hemp Beverages expands into North Carolina, leaning on “approachable dosages” and fruit-forward flavors as the market grows. Medical Cannabis & Cancer Care: A federally funded study in Frontiers in Psychiatry links cannabis use in cancer patients to symptom relief, with differences between THC+CBD users and CBD-only users, and flags insurance access as a barrier. Pet CBD Caution: The AVMA urges dog owners to be skeptical—research is limited, and many OTC CBD products aren’t held to the same safety standards as human meds. Policy Pressure on THC Products: The House is set to vote on delaying a federal hemp THC ban to Dec. 11, giving lawmakers more time to craft rules. Unregulated Retail Risks: Pennsylvania officials warn that “hemp” smoke shops may sell THC products above legal limits, with misleading labels and youth harm concerns.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
